{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:46:13Z","timestamp":1759365973339,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jaad.2022.03.019","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T21:30:23Z","timestamp":1647552623000},"page":"e33-e34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to: \u201cSpecial editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration\u2019s September 1, 2021, data safety communication\u201d"],"prefix":"10.1016","volume":"87","author":[{"given":"Jonathan W.","family":"Rick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2022.03.019_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaad.2021.09.051","article-title":"Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration\u2019s September 1, 2021, data safety communication","volume":"86","author":"Murphrey","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.03.019_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/1346-8138.15173","article-title":"Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis","volume":"47","author":"Nakagawa","year":"2020","journal-title":"J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2022.03.019_bib2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk Factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.03.019_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14563","article-title":"Activation of Janus kinase signaling pathway in\u00a0acne lesions","volume":"34","author":"Awad","year":"2021","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2022.03.019_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000371821","article-title":"Acneiform rash induced by EGFR inhibitors: review of the literature and new insights","volume":"1","author":"Fabbrocini","year":"2015","journal-title":"Skin Appendage Disord"},{"issue":"5","key":"10.1016\/j.jaad.2022.03.019_bib5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaad.2015.08.015","article-title":"Role of sebaceous glands in inflammatory dermatoses","volume":"73","author":"Shi","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222004820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222004820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:33Z","timestamp":1759273293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222004820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0190962222004820"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.03.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to: \u201cSpecial editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration\u2019s September 1, 2021, data safety communication\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}